RECURSION PHARMACEUTICALS, INC. (RXRX)

3.34 -2.91% (-0.10)

Over 1Y: -31.3%

2026-08-28
Style
Area Line Line with markers Steps Candlesneeds a shorter window Hollow candlesneeds a shorter window Barsneeds a shorter window

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

4 6
Aug Oct Dec Feb Apr Jun Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '25 — Revenue: 5.2M Q3 '25 — Operating Cash Flow: -117.4M Q3 '25 — Free Cash Flow: -117.6M Q3 '25 — Net Income: -162.3M Q4 '25 — Revenue: 35.5M Q4 '25 — Operating Cash Flow: -46.1M Q4 '25 — Free Cash Flow: -47.3M Q4 '25 — Net Income: -108.1M Q1 '26 — Revenue: 6.5M Q1 '26 — Operating Cash Flow: -81.1M Q1 '26 — Free Cash Flow: -81.4M Q1 '26 — Net Income: -117.5M Q2 '26 — Revenue: 7.7M Q2 '26 — Operating Cash Flow: -105.9M Q2 '26 — Free Cash Flow: -106M Q2 '26 — Net Income: -131M -160M -120M -80M -40M 0 40M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 165.4%
OE margin -807.6%
Oper. margin -991.7%
ROIC -112.1%
Accruals -13.9%
Asset turnover 0.045×
EBITDA margin -848.9%
FCF margin -642.2%
OCF margin -638.9%
Profit margin -945.9%
ROA -42.8%
ROCE -49.8%
ROE -56.7%
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

6.0
RPO / sales 0.5×
RPO growth —
Segment HHI —

4 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.5
ND/EBITDA —
Interest cover -367.3×
Cash / Debt 38.4×
Debt / Eq 0.016×
Debt payback 0.0 yr
Quick ratio 5.0×
Cash runway 1.5 yr
F-score 4.0 pts
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.8
Sales CAGR 4Y +64.6%
Sales/sh Y/Y -48.0%
Sales Q/Q -60.1%
Shares change +63.2%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.